Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02347111 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026 Site contacts updated at 1 of 4 sitesv14 Show 1 more changeShow less
    • Site contacts updated at 1 of 4 sites
  2. Eligibility criteria shortened, about 7 words Study description expanded, about 58 wordsv13 Show 1 more changeShow less
    • Study description expanded, about 58 words

    See this version in full on ClinicalTrials.gov ↗

  3. 3 versions Re-verified since May 16, 2022, no change to tracked fieldsv10-v12
  4. Primary and study completion dates: Jun 2026 to Jun 30, 2025 Start date: Apr 1, 2021 to Dec 31, 2020v9 Show 1 more changeShow less
    • Start date: Apr 1, 2021 to Dec 31, 2020
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2021 to Apr 1, 2021 · Site details revised at 4 of 4 sitesv8 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2021 to Apr 1, 2021
    • Site details revised at 4 of 4 sites
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: Jun 2025 to Jun 2026 Start date: Oct 2020 to Jan 2021v7 Show 1 more changeShow less
    • Start date: Oct 2020 to Jan 2021
  2. Start date: Jul 2020 to Oct 2020 Secondary endpoints: details revised at 1 of 1 entryv6 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 1 entry
  3. Enrollment target: 10 to 162 Primary and study completion dates: Jun 2020 to Jun 2025 · Start date: Feb 2015 to Jul 2020 · Trial status: Recruiting to Not Yet Recruiting · 4 morev5 Show 7 more changesShow less
    • Primary and study completion dates: Jun 2020 to Jun 2025
    • Start date: Feb 2015 to Jul 2020
    • Trial status: Recruiting to Not Yet Recruiting
    • Study sites: 1 to 4
    • Eligibility criteria expanded, about 20 words
    • Study description expanded, about 7 words
    • Secondary endpoints expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Lead sponsor: Vanderbilt University to University of Illinois at Chicago Trial status: Active, Not Recruiting to Recruiting · Primary completion date: Feb 2017 to Jun 2020 · Completion date: Jun 2017 to Jun 2020 · 3 morev4 Show 6 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Feb 2017 to Jun 2020
    • Completion date: Jun 2017 to Jun 2020
    • Study site revised
    • Eligibility criteria expanded, about 1 word
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  6. Trial status: Not Yet Recruiting to Recruiting Completion date: Jun 2017v2 Show 1 more changeShow less
    • Completion date: Jun 2017
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.
Trial Details
NCT Number NCT02347111
Lead Sponsor University of Illinois at Chicago
Collaborators: Medtronic
Conditions Atrial Fibrillation
Enrollment 162 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov